Nanoparticle-based supply techniques modulate the tumor microenvironment in pancreatic most cancers for enhanced remedy | Journal of Nanobiotechnology

Ilic M, Ilic I. Epidemiology of pancreatic most cancers. World J Gastroenterol. 2016;22(44):9694–705.

PubMed 
PubMed Central 

Google Scholar 

Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, et al. Pancreatic most cancers: yesterday, at present and tomorrow. Future Oncol. 2016;12(16):1929–46.

CAS 
PubMed 

Google Scholar 

Goral V. Pancreatic most cancers: pathogenesis and analysis. Asian Pac J Most cancers Prev. 2015;16(14):5619–24.

PubMed 

Google Scholar 

Lin QJ, Yang F, Jin C, Fu DL. Present standing and progress of pancreatic most cancers in China. World J Gastroenterol. 2015;21(26):7988–8003.

PubMed 
PubMed Central 

Google Scholar 

Carmicheal J, Patel A, Dalal V, Atri P, Dhaliwal AS, Wittel UA, et al. Elevating pancreatic cystic lesion stratification: present and future pancreatic most cancers biomarker(s). Biochim Biophys Acta Rev Most cancers. 2020;1873(1): 188318.

CAS 
PubMed 

Google Scholar 

Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine methods to beat the pathophysiological boundaries of pancreatic most cancers. Nat Rev Clin Oncol. 2016;13(12):750–65.

CAS 
PubMed 

Google Scholar 

Yang J, Ren B, Yang G, Wang H, Chen G, You L, et al. The enhancement of glycolysis regulates pancreatic most cancers metastasis. Cell Mol Life Sci. 2020;77(2):305–21.

CAS 
PubMed 

Google Scholar 

Wang S, Li Y, Xing C, Ding C, Zhang H, Chen L, et al. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic most cancers. Am J Most cancers Res. 2020;10(7):1937–53.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Karamitopoulou E. Tumour microenvironment of pancreatic most cancers: immune panorama is dictated by molecular and histopathological options. Br J Most cancers. 2019;121(1):5–14.

PubMed 
PubMed Central 

Google Scholar 

Nishida T, Yoshitomi H, Takano S, Kagawa S, Shimizu H, Ohtsuka M, et al. Low stromal space and excessive stromal microvessel density predict poor prognosis in pancreatic most cancers. Pancreas. 2016;45(4):593–600.

CAS 
PubMed 

Google Scholar 

Chen X, Zhou W, Liang C, Shi S, Yu X, Chen Q, et al. Codelivery nanosystem focusing on the deep microenvironment of pancreatic most cancers. Nano Lett. 2019;19(6):3527–34.

CAS 
PubMed 

Google Scholar 

Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic most cancers—scientific challenges and alternatives. Nat Rev Clin Oncol. 2020;17(9):527–40.

PubMed 
PubMed Central 

Google Scholar 

Kokkinos J, Ignacio RMC, Sharbeen G, Boyer C, Gonzales-Aloy E, Goldstein D, et al. Focusing on the undruggable in pancreatic most cancers utilizing nano-based gene silencing medication. Biomaterials. 2020;240: 119742.

CAS 
PubMed 

Google Scholar 

Wu J, Liang C, Chen M, Su W. Affiliation between tumor-stroma ratio and prognosis in stable tumor sufferers: a scientific evaluate and meta-analysis. Oncotarget. 2016;7(42):68954–65.

PubMed 
PubMed Central 

Google Scholar 

Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, et al. Angiogenesis in pancreatic most cancers: present analysis standing and scientific implications. Angiogenesis. 2019;22(1):15–36.

PubMed 

Google Scholar 

Selvanesan BC, Meena Ok, Beck A, Meheus L, Lara O, Rooman I, et al. Nicotinamide mixed with gemcitabine is an immunomodulatory remedy that restrains pancreatic most cancers in mice. J Immunother Most cancers. 2020;8(2): e001250.

PubMed 
PubMed Central 

Google Scholar 

Rocha FG. Landmark collection: immunotherapy and focused remedy for pancreatic most cancers. Ann Surg Oncol. 2021;28(3):1400–6.

PubMed 

Google Scholar 

Magri A, Baveloni FG, de Camargo BAF, Chorilli M. The rising landscapes to drug supply techniques for the therapy of pancreatic most cancers. Curr Med Chem. 2021;28(26):5411–30.

CAS 
PubMed 

Google Scholar 

Baetke SC, Lammers T, Kiessling F. Functions of NPs for analysis and remedy of most cancers. Br J Radiol. 2015;88(1054):20150207.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Ashfaq UA, Riaz M, Yasmeen E, Yousaf MZ. Current advances in nanoparticle-based focused drug-delivery techniques in opposition to most cancers and function of tumor microenvironment. Crit Rev Ther Drug Service Syst. 2017;34(4):317–53.

PubMed 

Google Scholar 

Yang S, Gao H. NPs for modulating tumor microenvironment to enhance drug supply and tumor remedy. Pharmacol Res. 2017;126:97–108.

CAS 
PubMed 

Google Scholar 

Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, et al. Microenvironmental determinants of pancreatic most cancers. Physiol Rev. 2020;100(4):1707–51.

PubMed 

Google Scholar 

Neesse A, Bauer CA, Öhlund D, Lauth M, Buchholz M, Michl P, et al. Stromal biology and remedy in pancreatic most cancers: prepared for scientific translation? Intestine. 2019;68(1):159–71.

CAS 
PubMed 

Google Scholar 

Hosein AN, Brekken RA, Maitra A. Pancreatic most cancers stroma: an replace on therapeutic focusing on methods. Nat Rev Gastroenterol Hepatol. 2020;17(8):487–505.

PubMed 
PubMed Central 

Google Scholar 

Cox TR. The matrix in most cancers. Nat Rev Most cancers. 2021;21(4):217–38.

CAS 
PubMed 

Google Scholar 

Wohlrab J, Wohlrab D, Wohlrab L, Wohlrab C, Wohlrab A. Use of hyaluronidase for pharmacokinetic enhance in bioavailability of intracutaneously utilized substances. Pores and skin Pharmacol Physiol. 2014;27(5):276–82.

CAS 
PubMed 

Google Scholar 

Zhong Y, Macgregor-Das A, Saunders T, Whittle MC, Makohon-Moore A, Kohutek ZA, et al. Mutant p53 along with TGFβ signaling affect organ-specific hematogenous colonization patterns of pancreatic most cancers. Clin Most cancers Res. 2017;23(6):1607–20.

CAS 
PubMed 

Google Scholar 

Sidhu I, Barwe SP, Gopalakrishnapillai A. The extracellular matrix: a key participant within the pathogenesis of hematologic malignancies. Blood Rev. 2021;48: 100787.

CAS 
PubMed 

Google Scholar 

Jang M, An J, Oh SW, Lim JY, Kim J, Choi JK, et al. Matrix stiffness epigenetically regulates the oncogenic activation of the Sure-associated protein in gastric most cancers. Nat Biomed Eng. 2021;5(1):114–23.

CAS 
PubMed 

Google Scholar 

Piersma B, Hayward MK, Weaver VM. Fibrosis and most cancers: a strained relationship. Biochim Biophys Acta Rev Most cancers. 2020;1873(2): 188356.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan WCW. Evaluation of nanoparticle supply to tumours. Nat Rev Mater. 2016. https://doi.org/10.1038/natrevmats.2016.14.

Article 

Google Scholar 

Korc M. Pancreatic cancer-associated stroma manufacturing. Am J Surg. 2007;194(4 Suppl):S84–6.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Girigoswami Ok, Saini D, Girigoswami A. Extracellular matrix transforming and growth of most cancers. Stem Cell Rev Rep. 2021;17(3):739–47.

PubMed 

Google Scholar 

Doherty GJ, Tempero M, Corrie PG. HALO-109-301: a Section III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic most cancers. Future Oncol. 2018;14(1):13–22.

CAS 
PubMed 

Google Scholar 

Sohr S, Engeland Ok. RHAMM is differentially expressed within the cell cycle and downregulated by the tumor suppressor p53. Cell Cycle. 2008;7(21):3448–60.

CAS 
PubMed 

Google Scholar 

Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, et al. Desmoplasia in major tumors and metastatic lesions of pancreatic most cancers. Clin Most cancers Res. 2015;21(15):3561–8.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook dinner N, Frese KK, et al. Hyaluronan impairs vascular perform and drug supply in a mouse mannequin of pancreatic most cancers. Intestine. 2013;62(1):112–20.

CAS 
PubMed 

Google Scholar 

Zhou H, Fan Z, Deng J, Lemons PK, Arhontoulis DC, Bowne WB, et al. Hyaluronidase embedded in nanocarrier PEG shell for enhanced tumor penetration and extremely environment friendly antitumor efficacy. Nano Lett. 2016;16(5):3268–77.

CAS 
PubMed 

Google Scholar 

Chen D, Zhu X, Tao W, Kong Y, Huag Y, Zhang Y, et al. Regulation of pancreatic most cancers microenvironment by an clever gemcitabine@nanogel system through in vitro 3D mannequin for selling therapeutic effectivity. J Management Launch. 2020;10(324):545–59.

Google Scholar 

Wang H, Han X, Dong Z, et al. Hyaluronidase with pH-responsive dextran modification as an adjuvant nanomedicine for enhanced photodynamic-immunotherapy of most cancers. Adv Funct Mater. 2019;29:1902440.

Google Scholar 

Weber GC, Buhren BA, Schrumpf H, Wohlrab J, Gerber PA. Scientific functions of hyaluronidase. Adv Exp Med Biol. 2019;1148:255–77.

CAS 
PubMed 

Google Scholar 

Xu S, Xu H, Wang W, Li S, Li H, Li T, et al. The function of collagen in most cancers: from bench to bedside. J Transl Med. 2019;17(1):309.

PubMed 
PubMed Central 

Google Scholar 

Egeblad M, Rasch MG, Weaver VM. Dynamic interaction between the collagen scaffold and tumor evolution. Curr Opin Cell Biol. 2010;22(5):697–706.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Chen IM, Willumsen N, Dehlendorff C, Johansen AZ, Jensen BV, Hansen CP, et al. Scientific worth of serum hyaluronan and propeptide of sort III collagen in sufferers with pancreatic most cancers. Int J Most cancers. 2020;146(10):2913–22.

CAS 
PubMed 

Google Scholar 

Villegas MR, Baeza A, Usategui A, Ortiz-Romero PL, Pablos JL, Vallet-Regí M. Collagenase nanocapsules: an method to fibrosis therapy. Acta Biomater. 2018;1(74):430–8.

Google Scholar 

Zinger A, Koren L, Adir O, Poley M, Alyan M, Yaari Z, et al. Collagenase NPs improve the penetration of medicine into pancreatic tumors. ACS Nano. 2019;13(10):11008–21.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Liang C, Shi S, Meng Q, Liang D, Ji S, Zhang B, et al. Do anti-stroma therapies enhance extrinsic resistance to extend the efficacy of gemcitabine in pancreatic most cancers? Cell Mol Life Sci. 2018;75(6):1001–12.

CAS 
PubMed 

Google Scholar 

Amoozgar Z, Goldberg MS. Floor modulation of polymeric nanocarriers enhances the soundness and supply of proteins and small molecules. Nanomedicine (Lond). 2017;12(7):729–43.

CAS 

Google Scholar 

Pan A, Wang Z, Chen B, Dai W, Zhang H, He B, et al. Localized co-delivery of collagenase and trastuzumab by thermosensitive hydrogels for enhanced antitumor efficacy in human breast xenograft. Drug Deliv. 2018;25(1):1495–503.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Dolor A, Szoka FC Jr. Digesting a path ahead: the utility of collagenase tumor therapy for improved drug supply. Mol Pharm. 2018;15(6):2069–83.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Knapinska AM, Estrada CA, Fields GB. The roles of matrix metalloproteinases in pancreatic most cancers. Prog Mol Biol Transl Sci. 2017;148:339–54.

CAS 
PubMed 

Google Scholar 

Yin N, Yu H, Zhang X, Lv X. Enhancement of pancreatic most cancers remedy efficacy by type-1 matrix metalloproteinase-functionalized NPs for the selective supply of gemcitabine and erlotinib. Drug Des Devel Ther. 2020;23(14):4465–75.

Google Scholar 

Kulkarni PS, Haldar MK, Nahire RR, Katti P, Ambre AH, Muhonen WW, et al. Mmp-9 responsive PEG cleavable nanovesicles for environment friendly supply of chemotherapeutics to pancreatic most cancers. Mol Pharm. 2014;11(7):2390–9.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Melstrom LG, Salazar MD, Diamond DJ. The pancreatic most cancers microenvironment: a real double agent. J Surg Oncol. 2017;116(1):7–15.

CAS 
PubMed 
PubMed Central 

Google Scholar 

von Ahrens D, Bhagat TD, Nagrath D, Maitra A, Verma A. The function of stromal cancer-associated fibroblasts in pancreatic most cancers. J Hematol Oncol. 2017;10(1):76.

Google Scholar 

Yu Q, Qiu Y, Li J, Tang X, Wang X, Cun X, et al. Focusing on cancer-associated fibroblasts by dual-responsive lipid-albumin NPs to boost drug perfusion for pancreatic tumor remedy. J Management Launch. 2020;10(321):564–75.

Google Scholar 

Biffi G, Tuveson DA. Variety and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101(1):147–76.

Google Scholar 

Giorello MB, Borzone FR, Labovsky V, Piccioni FV, Chasseing NA. Most cancers-associated fibroblasts within the breast tumor microenvironment. J Mammary Gland Biol Neoplasia. 2021;26(2):135–55.

PubMed 

Google Scholar 

Lakiotaki E, Sakellariou S, Evangelou Ok, Liapis G, Patsouris E, Delladetsima I. Vascular and ductal elastotic modifications in pancreatic most cancers. APMIS. 2016;124(3):181–7.

CAS 
PubMed 

Google Scholar 

Pereira BA, Vennin C, Papanicolaou M, Chambers CR, Herrmann D, Morton JP, et al. CAF subpopulations: a brand new reservoir of stromal targets in pancreatic most cancers. Tendencies Most cancers. 2019;5(11):724–41.

PubMed 

Google Scholar 

Linares J, Marín-Jiménez JA, Badia-Ramentol J, Calon A. Determinants and features of CAFs secretome throughout most cancers development and remedy. Entrance Cell Dev Biol. 2021;8: 621070.

PubMed 
PubMed Central 

Google Scholar 

Feng J, Xu M, Wang J, Zhou S, Liu Y, Liu S, et al. Sequential supply of nanoformulated α-mangostin and triptolide overcomes permeation obstacles and improves therapeutic results in pancreatic most cancers. Biomaterials. 2020;241: 119907.

CAS 
PubMed 

Google Scholar 

Jiang T, Zhang B, Zhang L, Wu X, Li H, Shen S, et al. Biomimetic NPs delivered hedgehog pathway inhibitor to switch tumour microenvironment and improved chemotherapy for pancreatic carcinoma. Artif Cells Nanomed Biotechnol. 2018;46(sup1):1088–101.

CAS 
PubMed 

Google Scholar 

Zhao J, Wang H, Hsiao CH, Chow DS, Koay EJ, Kang Y, et al. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic most cancers remedy. Biomaterials. 2018;159:215–28.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Hossen MN, Rao G, Dey A, Robertson JD, Bhattacharya R, Mukherjee P. Gold nanoparticle transforms activated cancer-associated fibroblasts to quiescence. ACS Appl Mater Interfaces. 2019;11(29):26060–8.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Cheng N, Bai X, Shu Y, Ahmad O, Shen P. Focusing on tumor-associated macrophages as an antitumor technique. Biochem Pharmacol. 2021;183: 114354.

CAS 
PubMed 

Google Scholar 

Peng H, Wang JH, Guo F, Zhu FF, Wen ZJ, Zhong HJ, et al. Legumain protease-activated tuftsin-functionalized nanoparticles for dual-targeting TAMs and most cancers chemotherapy. Colloids Surf B Biointerfaces. 2021;197: 111442.

CAS 
PubMed 

Google Scholar 

Cullis J, Siolas D, Avanzi A, Barui S, Maitra A, Bar-Sagi D. Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic most cancers. Most cancers Immunol Res. 2017;5(3):182–90.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Wang N, Wang S, Wang X, Zheng Y, Yang B, Zhang J, et al. Analysis traits in pharmacological modulation of tumor-associated macrophages. Clin Transl Med. 2021;11(1): e288.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Yokoi Ok, Godin B, Oborn CJ, Alexander JF, Liu X, Fidler IJ, et al. Porous silicon nanocarriers for twin focusing on tumor related endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers. Most cancers Lett. 2013;334(2):319–27.

CAS 
PubMed 

Google Scholar 

Li M, Li M, Yang Y, Liu Y, Xie H, Yu Q, et al. Transforming tumor immune microenvironment through focused blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor related macrophages for pancreatic most cancers remedy. J Management Launch. 2020;10(321):23–35.

CAS 

Google Scholar 

Das M, Shen L, Liu Q, Goodwin TJ, Huang L. Nanoparticle supply of RIG-I agonist permits efficient and secure adjuvant remedy in pancreatic most cancers. Mol Ther. 2019;27(3):507–17.

CAS 
PubMed 

Google Scholar 

Huang H, Jiang CT, Shen S, Liu A, Gan YJ, Tong QS, et al. Nanoenabled reversal of IDO1-mediated immunosuppression synergizes with immunogenic chemotherapy for improved most cancers remedy. Nano Lett. 2019;19(8):5356–65.

CAS 
PubMed 

Google Scholar 

Lu J, Liu X, Liao YP, Salazar F, Solar B, Jiang W, et al. Nano-enabled pancreas most cancers immunotherapy utilizing immunogenic cell dying and reversing immunosuppression. Nat Commun. 2017;8(1):1811.

PubMed 
PubMed Central 

Google Scholar 

Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, et al. Stimulation of tumor development and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med. 2009;15(4):392–400.

CAS 
PubMed 

Google Scholar 

Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79(7):1157–64.

CAS 
PubMed 

Google Scholar 

Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R. Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in growth for glioblastoma and different malignancies. Future Oncol. 2011;7(3):339–54.

CAS 
PubMed 

Google Scholar 

Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the primary anti-angiogenic small molecule drug candidate design, synthesis and scientific analysis. Anticancer Brokers Med Chem. 2010;10(10):753–68.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Wei Y, Tune S, Duan N, Wang F, Wang Y, Yang Y, et al. MT1-MMP-activated liposomes to enhance tumor blood perfusion and drug supply for enhanced pancreatic most cancers remedy. Adv Sci (Weinh). 2020;7(17):1902746.

CAS 

Google Scholar 

Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas most cancers with diminished survival. Most cancers Cell. 2014;25(6):719–34.

PubMed 
PubMed Central 

Google Scholar 

Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal components act to restrain, reasonably than assist, pancreatic ductal adenocarcinoma. Most cancers Cell. 2014;25(6):735–47.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Erkan M, Kurtoglu M, Kleeff J. The function of hypoxia in pancreatic most cancers: a possible therapeutic goal? Professional Rev Gastroenterol Hepatol. 2016;10(3):301–16.

CAS 
PubMed 

Google Scholar 

Hao X, Ren Y, Feng M, Wang Q, Wang Y. Metabolic reprogramming resulting from hypoxia in pancreatic most cancers: Implications for tumor formation, immunity, and extra. Biomed Pharmacother. 2021;141: 111798.

CAS 
PubMed 

Google Scholar 

Tao J, Yang G, Zhou W, Qiu J, Chen G, Luo W, et al. Focusing on hypoxic tumor microenvironment in pancreatic most cancers. J Hematol Oncol. 2021;14(1):14.

PubMed 
PubMed Central 

Google Scholar 

Donato C, Kunz L, Castro-Giner F, Paasinen-Sohns A, Strittmatter Ok, Szczerba BM, et al. Hypoxia triggers the intravasation of clustered circulating tumor cells. Cell Rep. 2020;32(10): 108105.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Feig C, Gopinathan A, Neesse A, Chan DS, Cook dinner N, Tuveson DA. The pancreas most cancers microenvironment. Clin Most cancers Res. 2012;18(16):4266–76.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Mu R, Zou YK, Tu Ok, Wang DB, Tang D, Yu Z, et al. Hypoxia promotes pancreatic most cancers cell dedifferentiation to stem-like cell phenotypes with excessive tumorigenic potential by the HIF-1α/notch signaling pathway. Pancreas. 2021;50(5):756–65.

CAS 
PubMed 

Google Scholar 

Lang J, Zhao X, Wang X, Zhao Y, Li Y, Zhao R, et al. Focused co-delivery of the iron chelator deferoxamine and a HIF1α inhibitor impairs pancreatic tumor development. ACS Nano. 2019;13(2):2176–89.

CAS 
PubMed 

Google Scholar 

Mizuno T, Nagao M, Yamada Y, Narikiyo M, Ueno M, Miyagishi M, et al. Small interfering RNA expression vector focusing on hypoxia-inducible issue 1 alpha inhibits tumor development in hepatobiliary and pancreatic cancers. Most cancers Gene Ther. 2006;13(2):131–40.

CAS 
PubMed 

Google Scholar 

Zhao X, Li F, Li Y, Wang H, Ren H, Chen J, et al. Co-delivery of HIF1α siRNA and gemcitabine through biocompatible lipid-polymer hybrid NPs for efficient therapy of pancreatic most cancers. Biomaterials. 2015;46:13–25.

CAS 
PubMed 

Google Scholar 

Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impression of particle dimension and polydispersity index on the scientific functions of lipidic nanocarrier techniques. Pharmaceutics. 2018;10(2):57.

PubMed Central 

Google Scholar 

Lin C, Hu Z, Yuan G, Su H, Zeng Y, Guo Z, et al. HIF1α-siRNA and gemcitabine combination-based GE-11 peptide antibody-targeted nanomedicine for enhanced therapeutic efficacy in pancreatic cancers. J Drug Goal. 2019;27(7):797–805.

CAS 
PubMed 

Google Scholar 

McEwan C, Owen J, Stride E, Fowley C, Nesbitt H, Cochrane D, et al. Oxygen carrying microbubbles for enhanced sonodynamic remedy of hypoxic tumours. J Management Launch. 2015;10(203):51–6.

Google Scholar 

Sheng Y, Beguin E, Nesbitt H, Kamila S, Owen J, Barnsley LC, et al. Magnetically responsive microbubbles as supply autos for focused sonodynamic and antimetabolite remedy of pancreatic most cancers. J Management Launch. 2017;28(262):192–200.

Google Scholar 

McEwan C, Kamila S, Owen J, Nesbitt H, Callan B, Borden M, et al. Mixed sonodynamic and antimetabolite remedy for the improved therapy of pancreatic most cancers utilizing oxygen loaded microbubbles as a supply automobile. Biomaterials. 2016;80:20–32.

CAS 
PubMed 

Google Scholar 

Chen J, Luo H, Liu Y, Zhang W, Li H, Luo T, et al. Oxygen-self-produced nanoplatform for relieving hypoxia and breaking resistance to sonodynamic therapy of pancreatic most cancers. ACS Nano. 2017;11(12):12849–62.

CAS 
PubMed 

Google Scholar 

Sheng Y, Nesbitt H, Callan B, Taylor MA, Love M, McHale AP, et al. Oxygen producing NPs for improved photodynamic remedy of hypoxic tumours. J Management Launch. 2017;28(264):333–40.

Google Scholar 

Tune M, Liu T, Shi C, Zhang X, Chen X. Bioconjugated manganese dioxide NPs improve chemotherapy response by priming tumor-associated macrophages towards M1-like phenotype and attenuating tumor hypoxia. ACS Nano. 2016;10(1):633–47.

CAS 
PubMed 

Google Scholar 

Yang G, Xu L, Chao Y, Xu J, Solar X, Wu Y, et al. Hole MnO₂ as a tumor-microenvironment-responsive biodegradable nano-platform for mixture remedy favoring antitumor immune responses. Nat Commun. 2017;8(1):902.

PubMed 
PubMed Central 

Google Scholar 

Abu Lila AS, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon: scientific problem and approaches to handle. J Management Launch. 2013;172(1):38–47.

CAS 
PubMed 

Google Scholar 

Shin SW, Jung W, Choi C, Kim SY, Son A, Kim H, et al. Fucoidan-manganese dioxide NPs potentiate radiation remedy by co-targeting tumor hypoxia and angiogenesis. Mar Medication. 2018;16(12):510.

CAS 
PubMed Central 

Google Scholar 

Pan W, Ge Y, Yu Z, Zhou P, Cui B, Li N, et al. A most cancers cell membrane-encapsulated MnO₂ nanoreactor for mixed photodynamic-starvation remedy. Chem Commun (Camb). 2019;55(35):5115–8.

CAS 

Google Scholar 

Li SY, Cheng H, Xie BR, Qiu WX, Zeng JY, Li CX, et al. Most cancers cell membrane camouflaged cascade bioreactor for most cancers focused hunger and photodynamic remedy. ACS Nano. 2017;11(7):7006–18.

CAS 
PubMed 

Google Scholar 

Liang D, Miller GH, Tranmer GK. Hypoxia activated prodrugs: components influencing design and growth. Curr Med Chem. 2015;22(37):4313–25.

CAS 
PubMed 

Google Scholar 

Gulfam M, Sahle FF, Lowe TL. Design methods for chemical-stimuli-responsive programmable nanotherapeutics. Drug Discov At present. 2019;24(1):129–47.

CAS 
PubMed 

Google Scholar 

Kulkarni P, Haldar MK, You S, Choi Y, Mallik S. Hypoxia-responsive polymersomes for drug supply to hypoxic pancreatic most cancers cells. Biomacromol. 2016;17(8):2507–13.

CAS 

Google Scholar 

Graham Ok, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in most cancers therapy. Int J Nanomed. 2018;4(13):6049–58.

Google Scholar 

Kulkarni P, Haldar MK, Katti P, Dawes C, You S, Choi Y, et al. Hypoxia responsive, tumor penetrating lipid NPs for supply of chemotherapeutics to pancreatic most cancers cell spheroids. Bioconjug Chem. 2016;27(8):1830–8.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Confeld MI, Mamnoon B, Feng L, Jensen-Smith H, Ray P, Froberg J, et al. Focusing on the tumor core: hypoxia-responsive NPs for the supply of chemotherapy to pancreatic tumors. Mol Pharm. 2020;17(8):2849–63.

CAS 
PubMed 
PubMed Central 

Google Scholar 

Ichihara H, Motomura M, Matsumoto Y. Therapeutic results and anti-metastasis results of cationic liposomes in opposition to pancreatic most cancers metastasis in vitro and in vivo. Biochem Biophys Res Commun. 2019;511(3):504–9.

CAS 
PubMed 

Google Scholar 

Lin G, Chen S, Mi P. Nanoparticles focusing on and transforming tumor microenvironment for most cancers theranostics. J Biomed Nanotechnol. 2018;14(7):1189–207.

CAS 
PubMed 

Google Scholar 

Galon J, Bruni D. Approaches to deal with immune sizzling, altered and chilly tumours with mixture immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218.

CAS 
PubMed 

Google Scholar 

Musetti S, Huang L. Nanoparticle-mediated transforming of the tumor microenvironment to boost immunotherapy. ACS Nano. 2018;12(12):11740–55.

CAS 
PubMed 

Google Scholar